Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07103174
PHASE2

A Study of MG-K10 Humanized Monoclonal Antibody Injection in Subjects With Atopic Dermatitis

Sponsor: Shanghai Mabgeek Biotech.Co.Ltd

View on ClinicalTrials.gov

Summary

This study is a multicenter, randomized, double-blind, parallel controlled phase II study. It is planned to include approximately 60 subjects with moderate to severe atopic dermatitis(AD) to evaluate the efficacy and safety of MG-K10 monotherapy in adult patients with moderate to severe AD, and to observe PK characteristics, PD effects and immunogenicity.

Official title: A Phase II Clinical Study on the Efficacy and Safety of MG-K10 Humanized Monoclonal Antibody Injection in Patients With Moderate to Severe Atopic Dermatitis

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

60

Start Date

2025-08-16

Completion Date

2027-12-16

Last Updated

2025-08-05

Healthy Volunteers

No

Interventions

BIOLOGICAL

MG-K10 placebo

Administer the drug once every 4 weeks for a total of 6 times

Locations (2)

Tower 5,No.34,Chunxiao Road No.122 Pudong District, Shanghai, 201203.p R. china

Shanghai, Shanghai Municipality, China

Hangzhou First People's Hospital

Zhejiang, 杭州, China